Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Clinical trial NCT05169567 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05169567
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Neoplasm Neoplasm Metastasis

Start date: 2022-03-11
Primary completion: 2024-02-08
Enrollment: 368

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.